Form 8-K - Current report:
SEC Accession No. 0001214659-23-001612
Filing Date
2023-02-03
Accepted
2023-02-03 16:30:33
Documents
12
Period of Report
2023-02-03
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 d1312308k.htm   iXBRL 8-K 27660
  Complete submission text file 0001214659-23-001612.txt   204672

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE alzn-20230203.xsd EX-101.SCH 3203
3 XBRL LABEL FILE alzn-20230203_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE alzn-20230203_pre.xml EX-101.PRE 22343
6 EXTRACTED XBRL INSTANCE DOCUMENT d1312308k_htm.xml XML 3826
Mailing Address 3500 LENOX RD. NE SUITE 1500 ATLANTA GA 30326
Business Address 3500 LENOX RD. NE SUITE 1500 ATLANTA GA 30326 844-722-6333
Alzamend Neuro, Inc. (Filer) CIK: 0001677077 (see all company filings)

IRS No.: 811822909 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 8-K | Act: 34 | File No.: 001-40483 | Film No.: 23586457
SIC: 2834 Pharmaceutical Preparations